Roche Diagnostics has announced that the US Food and Drug Administration (FDA) has cleared its cobas proⓇ integrated solutions, a new generation of Serum Work Area (clinical chemistry and immunochemistry) laboratory solution, designed to optimize lab operations. With the cobas pro integrated solutions, laboratories are now able to run tests faster on less equipment, automate manual tasks and deliver results more quickly to aid in treatment decisions.
Diagnostic laboratories are a critical component of the global healthcare system with in vitro diagnostics influencing up to 70% of all clinical decisions while accounting for only about 2% of total healthcare spending. Together, medical and lab professionals play a key role in delivering optimal patient care, yet they face increasing pressure to manage a growing number of samples, while delivering quality results faster and rising profitability.
“We are excited about the accelerated FDA clearance of the cobas pro integrated solutions, our new generation of Serum Work Area solutions inspired by our mission to help improve speed and reliability of treatment decisions for patients and their families,” said Thomas Schinecker, CEO Roche Diagnostics. “Reliable, fast and sustainable diagnostic solutions are vital for optimal clinical care delivery for patients, and a key element in the evolution of general healthcare quality.”
The latest innovation from Roche allows for up to 2,200 tests per hour with three modules working in parallel and synchronized to improve efficiency. Additionally, the cobas pro integrated solutions can boast up to 3¼ hours less operating time for a daily routine workload compared to cobas 6000, while 93% of Roche Immunoassays have reaction times of 18 minutes or less. Reducing the time in delivering results to physicians and patients across a number of therapeutic areas including pregnancy, core lab/HIV testing and blood screening, is vital to clinical decision making.
For more science news, straight to your inbox, join SelectScience today >>